Soligenix (SNGX)
(Delayed Data from NSDQ)
$3.98 USD
+0.11 (2.84%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $4.02 +0.04 (1.01%) 5:30 PM ET
NA Value
NA Growth NA Momentum NA VGMCompany Summary
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Company Summary
General Information
Soligenix Inc
29 EMMONS DRIVE SUITE B-10
PRINCETON, NJ 08540
Phone: 609-538-8200
Fax: 609-452-6467
Email: ir@soligenix.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/11/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.09 |
Current Year EPS Consensus Estimate | -5.10 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/11/2024 |